Navigation Links
Gene responsible for relapses in young leukemia patients
Date:10/26/2011

This press release is available in French.

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia. This is what a study by Dr. Maja Krajinovic published in the Blood, the journal of the American Society of Hematology, reveals Dr. Krajinovic is an investigator at the Sainte-Justine University Hospital Research Center, which is affiliated with the University of Montreal.

Dr. Krajinovic's team focused on asparaginase, one of the drugs in a chemotherapy "cocktail" administered to young patients during the intensification phase of their treatment.

They observed that E. coli asparaginase therapy was associated with an increase in relapses when administered to patients who had particular polymorphism (special form) of the ATF5 gene. In fact, this gene regulates asparagine synthetase, an enzyme that produces asparagine, which in turn feeds cancer cells.

"In the presence of this polymorphism that, as we demonstrated, modifies the transcription rate of the ATF5 gene, it is possible that the medication, rather than preventing the proliferation of leukemia cells by reducing the rate of asparagine, does just the opposite by creating feedback that triggers cancer cells to produce asparagine themselves," explains Dr. Krajinovic.

The discovery of a form of gene associated with high rates of relapse during treatment with E.coli asparaginase opens the door to the possibility of selecting a type of pharmacological treatment based on a patient's genetic profile, an approach that reflects the shift toward personalized medicine. "If a DNA test detects the implicated polymorphisms in children, it will be possible to predict the risk of relapse or side effects," exclaimed Dr. Krajinovic. "The clinician can then propose an alternative treatment or adjust the dose accordingly."

Since the introduction of combination chemotherapy, the rate of pediatric survival without relapse has skyrocketed to about 80%. Yet some patients still resist treatment or present side effects. Pharmacogenetic research strategies involve studying the reaction to each drug used for combined chemotherapy based on various patient genetic profiles so as to design treatment plans that increase efficacy and reduce side effects in patients. Dr. Krajinovic has published a number of similar studies that focus on antifolate, another drug used in combination regimens to treat acute lymphoblastic leukemia.


'/>"/>
Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related biology news :

1. Scientists identify microbes responsible for consuming natural gas in Deepwater Horizon spill
2. Tick responsible for equine piroplasmosis outbreak identified
3. Competition with humans responsible for decline of New Zealands endangered sea lions, study shows
4. Competition with humans responsible for decline of New Zealands endangered sea lions, study shows
5. Study finds golden algae responsible for killing millions of fish less toxic in sunlight
6. Researchers ID microbe responsible for methane from landfills
7. Gene responsible for severe osteoporosis disorder discovered
8. BUSM researchers uncover cellular mechanism responsible for chronic inflammation, Type 2 diabetes
9. U of M researcher helps unlock 30 new genes responsible for early onset puberty
10. Black aspergilli species responsible for infecting corn identified
11. Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... PUNE, India , May 3, 2016 ... Type (DNA Chip (Genomics, Drug Discovery, Gene ... Chips), End user (Academics Institutes, Diagnostics Centers), ... 2020" published by MarketsandMarkets, the market is ... 2020 from USD 7.63 Billion in 2015, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs ... on May 31st and June 1st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech ... driven conferences, will take place on June 7-8, 2016, at the New York Academy ... on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... According to ... , for definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery ... plan would be made. , New technology has enabled doctors to administer higher ...
Breaking Biology Technology: